Biomarin Pharmaceutical earnings were $523.9M for the trailing 12 months ending Mar 31, 2025, with 152.3% growth year over year. The latest BMRN earnings report on Mar 31, 2025 announced Q1 2025 earnings of $185.7M, up 48.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BMRN reported annual earnings of $426.9M, with 154.6% growth. The next BMRN earnings date is Aug 5, 2025.
BMRN past earnings growth
How has BMRN's earnings growth performed historically?
Biomarin Pharmaceutical Earnings Reports & History FAQ
What were Biomarin Pharmaceutical's earnings last quarter?
On BMRN's earnings call on Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q1 2025 earnings per share (EPS) of $0.97, up 106.38% year over year. Total BMRN earnings for the quarter were $185.69 million. In the same quarter last year, Biomarin Pharmaceutical's earnings per share (EPS) was $0.47.
When does Biomarin Pharmaceutical report earnings?
The next BMRN earnings call is Invalid Date. Add BMRN to your watchlist to be reminded of Biomarin Pharmaceutical's next earnings date.
Is Biomarin Pharmaceutical profitable or losing money?
As of the last Biomarin Pharmaceutical earnings report, Biomarin Pharmaceutical is currently profitable. Biomarin Pharmaceutical's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $523.88 million, a 154.99% increase year over year.
What was BMRN's earnings growth in the past year?
As of Biomarin Pharmaceutical's earnings date in Invalid Date, Biomarin Pharmaceutical's earnings has grown 152.29% year over year. This is 141.07 percentage points higher than the US Biotechnology industry earnings growth rate of 11.23%. BMRN earnings in the past year totalled $523.88 million.
What are Biomarin Pharmaceutical's earnings expectations?
The current EPS estimate for Biomarin Pharmaceutical's earnings report in Invalid Date is $0.83.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.